Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus

Michaela Onstad, Jennifer Ducie, Bryan M. Fellman, Nadeem R. Abu-Rustum, Mario Leitao, Andrea Mariani, Francesco Multinu, Karen H. Lu, Pamela Soliman

Research output: Contribution to journalArticle

Abstract

Background: Patients with grade 3, deeply invasive endometrioid adenocarcinoma are typically managed with primary surgery. The role and type of adjuvant therapy used is controversial. We sought to evaluate the role of adjuvant radiation and/or chemotherapy in women with deeply invasive grade 3 endometrioid tumors. Methods: A multi-center retrospective chart review was performed at three large medical institutions in the United States. Patients with grade 3 endometrioid adenocarcinoma invading >50% of the myometrium were included. Medical records were queried to evaluate whether lymph node assessment was performed, the status of the lymph nodes, adjuvant treatment strategy used, and dates of death or recurrence. Results: Between 1984 and 2013, 257 patients were identified with a median follow-up of 3.08 years. Most patients (84.7%) had evaluation of pelvic and/or para-aortic lymph nodes and 43% had positive lymph nodes. For node negative patients, there was no difference in overall survival (OS) between those who received adjuvant pelvic radiation +/- vaginal brachytherapy (n=52) vs brachytherapy alone (n=46) (5-year probabilities were 0.73 vs 0.70, P=0.729). Among patients with positive lymph nodes (n=92), the adjuvant treatment strategy utilized impacted OS, with women undergoing a combination of chemotherapy and external beam radiation having the best outcomes (P=0.003). Conclusions: Among women with grade 3, deeply invasive endometrioid adenocarcinoma, vaginal cuff brachytherapy alone resulted in similar survival when compared with pelvic radiation in node negative patients. The combination of chemotherapy with external beam radiation was associated with improved OS for women with positive nodes.

Original languageEnglish
Article number000807
JournalInternational Journal of Gynecological Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2020

Keywords

  • endometrial neoplasms
  • lymph nodes
  • pathology
  • radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus'. Together they form a unique fingerprint.

  • Cite this

    Onstad, M., Ducie, J., Fellman, B. M., Abu-Rustum, N. R., Leitao, M., Mariani, A., Multinu, F., Lu, K. H., & Soliman, P. (Accepted/In press). Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. International Journal of Gynecological Cancer, [000807]. https://doi.org/10.1136/ijgc-2019-000807